Pembrolizumab Moves Toward EU Approval for Resected Stage IIB/IIC Melanoma

The European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended the approval of pembrolizumab (Keytruda) for use as adjuvant therapy in adult and adolescent patients aged 12 years and older with stage IIB or IIC melanoma following complete resection. Additionally, CHMP recommended expanding the indication for pembrolizumab in advanced unresectable or metastatic and stage III melanoma as adjuvant therapy following complete resection for adolescent patients aged 12 years and older.

Read More
MRV News
Melanoma News